Astrazeneca Pharma India Ltd (ASTRAZEN)
₹8,005.50
Mkt cap
₹20,014 Cr
P/E ratio
105.00
P/B
22.94
Div yield
0.45%
ROE
23.30%
ROCE
29.30%
EPS (TTM)
₹76.24
Book value
₹349
52W range
7,766–9,828
Sector
Healthcare
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. [1]
Health check
Cautious
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−18.54% from high₹8,006
₹7,766+3.09% from low₹9,828
Current
₹8,005.50
Prev close
₹8,000.00
Day
+0.07%
Price performance
1D
+0.07%
1W
−0.61%
1M
−4.59%
3M
−5.82%
6M
−2.97%
1Y
−14.78%
YTD
−6.93%
Financials
FRevenue, profit & margin
P/E ratio
105.0×
ASTRAZEN is 209% above the sector median of 34.0×
ASTRAZEN105.0×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | |
| Expenses | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | |
| Operating Profit | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | |
| OPM % | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | |
| Other Income | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | |
| Interest | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | |
| Profit before tax | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | |
| Tax % | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | |
| Net Profit | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | |
| EPS in Rs | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.56% · closed higher next day 16 of last 57
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Aug '23◦ | 9 Nov '23◦ | 8 Feb '24◦ | 28 May '24 | 8 Aug '24◦ | 14 Nov '24 | 11 Feb '25◦ | 30 May '25◦ | 14 Aug '25 | 7 Nov '25◦ | 11 Feb '26◦ | 26 May '26◦ |
| Earnings day | +0.99% | −5.29% | −12.90% | +0.47% | +1.24% | −4.99% | +0.68% | +17.12% | −1.21% | +0.06% | −2.69% | −3.51% |
| +1 day | +4.75% | −5.73% | −17.14% | −0.94% | −1.32% | −10.00% | −0.71% | +17.12% | −0.02% | +0.80% | −1.64% | −3.69% |
| +5 days | +5.33% | −5.27% | −16.24% | −12.33% | +0.04% | −9.42% | −6.51% | +26.15% | +0.20% | +0.69% | −1.82% | −5.00% |
| +15 days | +9.27% | −1.63% | −17.06% | −0.83% | +1.29% | −6.86% | +0.25% | +11.34% | +7.47% | −0.12% | −4.01% | −4.84% |
| +30 days | +12.85% | +13.25% | −22.64% | +4.98% | +1.89% | +2.48% | +15.57% | +15.21% | +5.64% | +0.63% | −14.36% | −9.43% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 36 Per Share | 36.00 | 31 Jul '26 | 31 Jul '26 |
Shareholding
Sas of Jun 202675.00%Promoter
Promoters75.00%
FIIs2.68%0.10
DIIs6.08%0.29
Public16.24%0.18
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Astrazeneca Phar | ₹8,005.50 | 104.61 | 20,014 | 0.45% | 45 | −26.63% | 579 | +20.42% | 29.26% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2013nse
Concall transcripts16
Announcements5
Communication To The Shareholders W.R.T. TDS On Dividend 2d - Shares TDS notice for final dividend ₹36/share; AGM August 10, record date July 31, 2026.Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) 21 Jul - Bhavana Agrawal resigns as CFO effective August 31, 2026, after moving to a regional AstraZeneca role.Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Jul - Please find the enclosed intimation of the Company as per the captioned subject for your reference.Record Date For Payment Of Final Dividend 18 JulBusiness Responsibility and Sustainability Reporting (BRSR) 18 Jul - Filed FY2025-26 Business Responsibility and Sustainability Report with limited assurance by KPMG.